



Anandamida

G A R D E N S

ENDOCANNABINOID SCIENCE

Disclaimer and cautionary note on forward-looking statements

This presentation ("Presentation") contains information about Anandamida Gardens S.A.S. (the "Company", "we", or "our"). Under no circumstances may the content of this Presentation be reproduced, in whole or in part, in any form or forwarded or redistributed to another person. Any forwarding, distribution or reproduction of this document in whole or in part is not authorized. By accepting and reviewing this document, you acknowledge and agree to maintain the confidentiality of this document and the information contained in this document, protect such information in the same way that you protect your own confidential information, which will be at least a reasonable standard of care and not use any of the information contained in this document, except to assist you with your evaluation of the Company.

This presentation is for informational purposes only and does not constitute an offer to sell or a request for an offer to purchase Company securities. This presentation is not, and under no circumstances will it be interpreted as a prospectus, offering memorandum, advertisement or public offering of securities. The information in this document has been prepared in order to provide general information to interested parties to assist them in their evaluation of the Company. In this presentation, all dollar values are in American dollars, unless otherwise noted.

Certain statements in this Presentation constitute "forward-looking statements" within the meaning of applicable Northamerican securities laws. Forward-looking statements are not historical facts or guarantees of future action. Instead, they are based on our current beliefs, expectations, assumptions, and analyzes made by us regarding the future of our business, future plans and strategies, our operating results, and other future conditions. Such forward-looking statements may be identified using words, such as "anticipates" or "believes", "budget", "estimates", "expects" or "is expected", "forecasts", "intends", "plans", "scheduled" or variations of such words and phrases or affirm that certain actions, events or results "may", "could", "will be", "would be", "could", "should", "will continue", or will be taken, will occur or will be achieved. These forward-looking statements refer to, among other things, our future financial performance, financial condition, liquidity, activity levels, the scalability of our business, our projected production capacity, the potential size of the cannabis and cannabinoid derivatives market, our competitive advantages compared to other jurisdictions in growth, market strategy, performance, prospects, growth, objectives or achievements or other future events. Although we base the forward-looking statements contained in this presentation on assumptions that we consider reasonable, these forward-looking statements involve risks, uncertainties, and other known and unknown factors that may cause actual performance and financial results in future periods to differ materially from those anticipated in our forward-looking statements.

Without limitation, these risks include risks related to the regulation of cannabis and cannabinoid derivatives in Northamerica, Colombia and other global markets, lack of significant income and dependence on external financing for growth, market demand and competition. Forward-looking statements disregard the effect that non-recurring transactions or items or other special items announced or occurred after the statements are made have on our business. For example, they do not include the effect of the asset, impairments or other charges announced or occurring after the forward-looking statements. The financial impact of such transactions and non-recurring items and other special items can be complex and necessarily depends on the particular facts of each of them.

Despite a careful process for preparing and reviewing forward-looking statements, the underlying opinions, estimates and assumptions cannot be guaranteed to be correct. The purpose of the forward-looking statements is to provide the reader with a description of management's expectations regarding our anticipated future performance and may not be appropriate for other purposes. Due to these risks, uncertainties and assumptions, the reader should not place undue reliance on these forward-looking statements. The Company's forward-looking statements are made only as of the date of this presentation, and except as required by applicable law, the Company assumes no obligation to update or revise these forward-looking statements to reflect new information, events or future circumstances. . The forward-looking statements contained in this document are expressly qualified by this warning statement.

Market Research and Public Data - This presentation also contains or references certain market, industry, and peer group data that is based on information from independent industry publications, market research, analyst reports and surveys, and other available sources. publicly. Although we believe that these sources are generally reliable, such information is subject to interpretation and cannot be verified with complete certainty to limit the availability and reliability of raw data, the voluntary nature of the data collection process, and other inherent limitations and uncertainties. We have not independently verified any of the data from third-party third-party sources referenced in this Submission, and therefore the accuracy and completeness of such data is not guaranteed.

Future-oriented financial information: to the extent that any forward-looking information in this Presentation constitutes "future-oriented financial information" or "financial perspectives" within the meaning of the applicable Colombian securities laws, such information is provided to demonstrate the Advance market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial perspectives. Forward-looking financial information and financial perspectives, as with forward-looking information in general, are, without limitation, based on assumptions and subject to the risks set forth above. Our actual financial position and results of operations may differ materially from current management expectations and, as a result, our income and profitability may differ materially from the income and profitability profiles provided in this Presentation. Such information is presented for illustrative purposes only and may not be an indication of our actual financial position or results of operations.

Use of non-GAAP measures: This document refers to EBITDA because this information can be used to evaluate our performance and also determine our ability to generate cash flow. These data are provided to provide additional information and are non-GAAP measures and do not have any standardized meaning prescribed by GAAP. They should not be considered in isolation as a substitute for performance measures prepared under GAAP and are not necessarily indicative of operating costs presented under GAAP.

About Us

Colombian company licensed
for cannabis cultivation, research
and manufacture of derivatives
for medicinal purposes.

*"Clinical Cannabis has become a therapeutic compass
to what modern medicine fails to cure"*

Dr. Ethan Russo

What we have done


We have achieved brand recognition in Colombia and Latin America. Our cultivars are registered with the Colombian Agropecuary Institute (ICA) and we are getting ready for commercial production for local and export markets. We have developed cannabinoid formulas rich in terpenoids for the treatment of chronic diseases and we have a broad medical network in Colombia, which we support with continuing education programs.

Anandamide is a neurotransmitter that mimics the effects of compounds present in the cannabis plant, called cannabinoids. Its name derives from the Sanskrit word "ananda" which means inner bliss.

Investment prospects

① Global trend

The global medical cannabis market is expected to account for \$ 90.83 billion by 2027.



Source: Data Bridge Market Research 2020

*CAGR: Compound annual growth rate

Investment prospects


② Solid legal framework

The Colombian Government has developed a robust legislation that allows the development of the local market, exports, scientific research, and access to patients.




Investment prospects

③ Competitiveness and geographical location



Production area with high level of security and connectivity, close to José María Córdova International Airport.



Optimal cultivation variables with 12 hours of sunlight, stable temperatures and access to cost efficient, sustainable and clean water.

Low cost production, high standards and qualified agricultural labor.



16 commercial agreements that support international trade from Colombia.




Area with wide agro-industrial and exports experience.



Our location

Agro-industrial cluster in Eastern Antioquia less than 20 minutes away from Rionegro's Free Trade Zone, the JMC International Airport, the municipality of Rionegro and 30 minutes away from Medellín through the Oriente Tunnel.



Our business model



Our milestones and projections

2019

JAN 30 Cannabis-derived manufacturing license



MAY 29 License to use cannabis seeds



OCT 11 Non-psychoactive cannabis cultivation license



DEC 16 Psychoactive cannabis cultivation license



DEC 17 Seedling source resolution (106 varieties)



2020

MAR/JUL Non-psychoactive agronomic evaluation test



JUL 22 Approval of psychoactive quotas



JUL/OCT Psychoactive agronomic evaluation test



AUG/DEC Greenhouse construction for production



SEP/DEC Laboratory construction for extraction



OCT Beginning of non-psychoactive commercial cultivation



2021

JAN Export finished product



MAY Beginning of psychoactive commercial cultivation




Our facilities



El Tablazo, Rionegro, Antioquia

- Mother plants greenhouse
- Agronomic evaluation greenhouse
- Production greenhouse
- Extraction lab
- Offices





Our greenhouses





- Superventilated type
- Anti thrips mesh enclosure
- Polyethylene for maximum use of solar radiation
- Automated drip irrigation system

Total production greenhouse area

2020	10.000 m2
2021	15.000 m2
2022	20.000 m2
2023	30.000 m2
2024	40.000 m2
2025	50.000 m2



Projection of results as for 2021-2025



Product development

● FULL SPECTRUM PHYTOTHERAPEUTICS AND MAGISTRAL FORMULAS

CBD Oral solution
Dropper bottle
30mL and 10mL
Cannabidiol:
50mg/mL
Tetrahydrocannabinol:
< 2mg/mL



THC Oral solution
Dropper bottle
30mL and 10mL
Tetrahydrocannabinol:
50mg/mL
Cannabidiol:
< 2mg/mL



CBD/THC Oral solution
Dropper bottle
30mL and 10mL
Cannabidiol:
50mg/mL
Tetrahydrocannabinol:
50mg/mL



● FULL SPECTRUM STANDARDIZED CANNABIS EXTRACT

CBD
1000mL Bulk
Cannabidiol: 5%
Tetrahydrocannabinol: < 0.2%



THC
1000mL Bulk
Tetrahydrocannabinol: 5%
Cannabidiol: < 0.2%



CBD/THC
1000mL Bulk
Cannabidiol: 5%
Tetrahydrocannabinol: 5%



Medical education programs



Endomedicine is a medical area of focus that deals with prevention, diagnosis and treatment of chronic diseases through modulation of the Human Endocannabinoid System (ECS).



- **2016** First Symposium on Medicinal Cannabis
300 attending physicians and students
Faculty of Medicine Universidad del Cauca
- **2019** International Seminar on Endomedicine
500 health professionals attendees
Parque Telemedellín
- **2020** Endomedicine Webinar
1000 attendees from 29 countries
Webinar for health professionals
- **2020/2021** Endomedicine Course:
medicinal cannabis and complementary
therapies aimed at health professionals

Main cannabis companies in Colombia

Company	Ticker	*Market Cap
Pharmacielo	PCLO	73.84M
Khiron Life Sciences	KHRN	59.21M
Avicanna	AVCN	36.43M
Blueberries Medical	BBN	4.54M
Medcolcanna	MCCN	7.68M
*CDN\$ (as of July 24 - 2020)		

Strategic allies



www.endomedicina.com



www.tni.org



www.analdex.org



www.cannabisclinicians.org



www.asocolcanna.org



www.grupocurativa.com



www.fundaciondaya.org



www.unicauca.edu.co



www.bancoagrario.gov.co



www.alpharma.com.co



www.asisfarma.com.co



www.empirialabs.com



www.labmedick.com

Board of advisors



Ethan Russo
CERTIFIED NEUROLOGIST
Founder of Cannabis Research.org
Medical Director at CReDO Science.



Mara Gordon
HEAD OF PROCESS ENGINEER
Researcher and
Co-founder of Aunt Zelda's California.



Paola Pineda
SURGEON AND RESEARCHER
Medical Director
at Grupo Curativa Colombia.



Cristina Sánchez
BIOLOGIST AND RESEARCHER
Professor at Universidad Complutense de Madrid.



José Rodríguez Orenco
CHEMIST AND RESEARCHER
Professor at the School of Medicine University of Puerto Rico.



Garrett Seale
NEUROSCIENTIST AND RESEARCHER
Brown university U.S.A.

Our team

Jaime Ignacio Gutiérrez
PRESIDENT

Julián Caicedo
MANAGING DIRECTOR

José Joaquín Varela
CHIEF SCIENTIFIC

Freddy Guarín
COMMERCIAL DIRECTOR

Diana Paola Valenzuela
LEGAL DIRECTOR

Alexander Gómez
CHIEF OF COMMUNICATIONS

Santiago Bravo
CHIEF OF LOGISTICS

Juliana Hernández
ADMINISTRATIVE LEADER

Zoraida Gutiérrez
OPERATIONAL DIRECTOR

Fáber de Jesús Chica
CHIEF OF CULTIVATION

Adrián López
AGRONOMIST

Lina María Escobar
TECHNICAL DIRECTOR (E)



Carrera 48 No. 16 - 30
Medellín, Colombia.

Contact: (4) 5 575811
info@anandamidagardens.com

Investor relations:
Jaime Ignacio Gutierrez
jaime.gutierrez@anandamidagardens.com

Visit our website:
www.anandamidagardens.com

Follow us in:

